Tempest Therapeutics Inc Stock
Tempest Therapeutics Inc Stock price
Key metrics
| Market capitalization | $24.67m |
| Enterprise Value | $16.27m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 2.12 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-44.99m |
| Free Cash Flow (TTM) Free Cash Flow | $-34.14m |
| Cash position | $21.51m |
Is Tempest Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Tempest Therapeutics Inc Stock Analysis
Analyst Opinions
3 Analysts have issued a Tempest Therapeutics Inc forecast:
Analyst Opinions
3 Analysts have issued a Tempest Therapeutics Inc forecast:
Financial data from Tempest Therapeutics Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.37 -0.37 |
69%
69%
|
|
| EBITDA | -45 -45 |
57%
57%
|
EBIT (Operating Income) EBIT | -45 -45 |
52%
52%
|
| Net Profit | -45 -45 |
51%
51%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Tempest Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tempest Therapeutics Inc Stock News
Company Profile
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Stephen Brady |
| Employees | 25 |
| Founded | 2011 |
| Website | www.tempesttx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
